Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новая фиксированная комбинация периндоприла, индапамида и амлодипина. «Три в одном» – путь к улучшению результатов терапии артериальной гипертонии
Новая фиксированная комбинация периндоприла, индапамида и амлодипина. «Три в одном» – путь к улучшению результатов терапии артериальной гипертонии
Темникова Е.А. Новая фиксированная комбинация периндоприла, индапамида и амлодипина. «Три в одном» – путь к улучшению результатов терапии артериальной гипертонии. Системные гипертензии. 2017; 14 (2): 65–68. DOI: 10.26442/2075-082X_14.2.65-68
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ведение пациентов с артериальной гипертонией остается сложной проблемой даже при использовании современных гипотензивных препаратов. Причины недостаточного контроля уровня артериального давления при лечении различны. Применение фиксированных комбинаций антигипертензивных препаратов улучшает результаты терапии, влияя на различные патогенетические механизмы повышения артериального давления и нивелируя контррегуляторные эффекты, возникающие при лечении каждым из компонентов комбинации. Применение фиксированных комбинаций значительно повышает приверженность пациентов лечению. Новая фиксированная тройная комбинация периндоприла, индапамида, амлодипина расширяет терапевтические возможности лечения артериальной гипертонии. Эффективность применения каждого из компонентов и их сочетания доказана в крупных международных исследованиях.
Ключевые слова: артериальная гипертония, комбинированная антигипертензивная терапия, фиксированные комбинации, периндоприл, амлодипин, индапамид.
Key words: arterial hypertension, combination antihypertension therapy, fixed combinations, perindopril, amlodipine, indapamide.
Ключевые слова: артериальная гипертония, комбинированная антигипертензивная терапия, фиксированные комбинации, периндоприл, амлодипин, индапамид.
________________________________________________
Key words: arterial hypertension, combination antihypertension therapy, fixed combinations, perindopril, amlodipine, indapamide.
Полный текст
Список литературы
1. WHO. A global brief on hypertension. Silent killer, global public health crisis. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/
2. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2224–60.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–8.
4. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
5. Ikeda N, Sapienz D, Guerrero R et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014; 92 (1): 10–9.
6. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных АГ. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh AG. Kardiologiia. 2014; 10: 4–12. [in Russian]
7. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4–14. / Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
8. Оганов Р.Г., Константинов В.В., Тимофеева Т.Н. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваск. терапия и профилактика. 2011; 10 (1): 9–13. / Oganov R.G., Konstantinov V.V., Timofeeva T.N. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
9. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Алимова Э.Э. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11–8. / Leonova M.V., Belousov Yu.B., Shteinberg L.L., Alimova E.E. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–8. [in Russian]
10. Чазова И.Е., Ратова Л.Г. Комбинированная терапия у пациентов с артериальной гипертонией. Системные гипертензии. 2010; 7 (2): 6–10. / Chazova I.E., Ratova L.G. The combination therapy in patients with arterial hypertension. Systemic Hypertension. 2010; 7 (2): 6–10. [in Russian]
11. Oganov RG, Pogosova GN, Koltunov IE et al. Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. Eur J Cardiovasc Prev Rehabil 2011; 18 (2): 224–32.
12. Шальнова С.А., Балабанова Ю.А., Константинов В.В. и др. Артерильная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–60. / Shal'nova S.A., Balabanova Iu.A., Konstantinov V.V. i dr. Arteril'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–60. [in Russian]
13. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15–8.
14. Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справочник поликлинического врача. 2007; 6: 8–11. / Konradi A.O. Znachenie priverzhennosti k terapii v lechenii kardiologicheskikh zabolevanii. Handbook for Practitioners Doctors. 2007; 6: 8–11. [in Russian]
15. Погосова Г.В., Колтунов И.Е., Мелик-Оганджанян Г.Ю., Соколова О.Ю. Приверженность к лечению сердечно-сосудистых заболеваний: проблема врачей и пациентов. Кардиоваск. терапия и профилактика. 2009; 8 (4): 98–102. / Pogosova G.V., Koltunov I.E., Melik-Ogandzhanian G.Iu., Sokolova O.Iu. Priverzhennost' k lecheniiu serdechno-sosudistykh zabolevanii: problema vrachei i patsientov. Kardiovask. terapiia i profilaktika. 2009; 8 (4): 98–102. [in Russian]
16. Mancia G, Fagard R, Narkiewicz R et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31 (7): 1281–357.
17. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
18. Epstein BJ, Shah NK, Borja-Hart N. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013; 7: 246–59.
19. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 869–78.
20. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 2009; 3: 231–40.
21. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension 2009; 54: 19–22.
22. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
23. Ettehad D, Emdin CA, Kiran A. Anderson SG et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–67.
24. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
25. Tropeano A, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80–6.
26. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
27. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
28. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108 (9): 710–7.
29. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102 (13): 1503–10.
30. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366 (948): 895–906.
31. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic : a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15: 193–200.
32. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs 2014; 14: 137–45.
33. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
34. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther 2017; 6 (1): 91–104.
2. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2224–60.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–8.
4. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
5. Ikeda N, Sapienz D, Guerrero R et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014; 92 (1): 10–9.
6. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh AG. Kardiologiia. 2014; 10: 4–12. [in Russian]
7. Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
8. Oganov R.G., Konstantinov V.V., Timofeeva T.N. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
9. Leonova M.V., Belousov Yu.B., Shteinberg L.L., Alimova E.E. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–8. [in Russian]
10. Chazova I.E., Ratova L.G. The combination therapy in patients with arterial hypertension. Systemic Hypertension. 2010; 7 (2): 6–10. [in Russian]
11. Oganov RG, Pogosova GN, Koltunov IE et al. Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. Eur J Cardiovasc Prev Rehabil 2011; 18 (2): 224–32.
12. Shal'nova S.A., Balabanova Iu.A., Konstantinov V.V. i dr. Arteril'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–60. [in Russian]
13. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15–8.
14. Konradi A.O. Znachenie priverzhennosti k terapii v lechenii kardiologicheskikh zabolevanii. Handbook for Practitioners Doctors. 2007; 6: 8–11. [in Russian]
15. Pogosova G.V., Koltunov I.E., Melik-Ogandzhanian G.Iu., Sokolova O.Iu. Priverzhennost' k lecheniiu serdechno-sosudistykh zabolevanii: problema vrachei i patsientov. Kardiovask. terapiia i profilaktika. 2009; 8 (4): 98–102. [in Russian]
16. Mancia G, Fagard R, Narkiewicz R et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31 (7): 1281–357.
17. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
18. Epstein BJ, Shah NK, Borja-Hart N. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013; 7: 246–59.
19. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 869–78.
20. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 2009; 3: 231–40.
21. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension 2009; 54: 19–22.
22. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
23. Ettehad D, Emdin CA, Kiran A. Anderson SG et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–67.
24. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
25. Tropeano A, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80–6.
26. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
27. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
28. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108 (9): 710–7.
29. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102 (13): 1503–10.
30. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366 (948): 895–906.
31. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic : a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15: 193–200.
32. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs 2014; 14: 137–45.
33. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
34. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther 2017; 6 (1): 91–104.
2. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2224–60.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–8.
4. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
5. Ikeda N, Sapienz D, Guerrero R et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014; 92 (1): 10–9.
6. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных АГ. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh AG. Kardiologiia. 2014; 10: 4–12. [in Russian]
7. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4–14. / Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
8. Оганов Р.Г., Константинов В.В., Тимофеева Т.Н. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваск. терапия и профилактика. 2011; 10 (1): 9–13. / Oganov R.G., Konstantinov V.V., Timofeeva T.N. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
9. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Алимова Э.Э. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11–8. / Leonova M.V., Belousov Yu.B., Shteinberg L.L., Alimova E.E. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–8. [in Russian]
10. Чазова И.Е., Ратова Л.Г. Комбинированная терапия у пациентов с артериальной гипертонией. Системные гипертензии. 2010; 7 (2): 6–10. / Chazova I.E., Ratova L.G. The combination therapy in patients with arterial hypertension. Systemic Hypertension. 2010; 7 (2): 6–10. [in Russian]
11. Oganov RG, Pogosova GN, Koltunov IE et al. Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. Eur J Cardiovasc Prev Rehabil 2011; 18 (2): 224–32.
12. Шальнова С.А., Балабанова Ю.А., Константинов В.В. и др. Артерильная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–60. / Shal'nova S.A., Balabanova Iu.A., Konstantinov V.V. i dr. Arteril'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–60. [in Russian]
13. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15–8.
14. Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справочник поликлинического врача. 2007; 6: 8–11. / Konradi A.O. Znachenie priverzhennosti k terapii v lechenii kardiologicheskikh zabolevanii. Handbook for Practitioners Doctors. 2007; 6: 8–11. [in Russian]
15. Погосова Г.В., Колтунов И.Е., Мелик-Оганджанян Г.Ю., Соколова О.Ю. Приверженность к лечению сердечно-сосудистых заболеваний: проблема врачей и пациентов. Кардиоваск. терапия и профилактика. 2009; 8 (4): 98–102. / Pogosova G.V., Koltunov I.E., Melik-Ogandzhanian G.Iu., Sokolova O.Iu. Priverzhennost' k lecheniiu serdechno-sosudistykh zabolevanii: problema vrachei i patsientov. Kardiovask. terapiia i profilaktika. 2009; 8 (4): 98–102. [in Russian]
16. Mancia G, Fagard R, Narkiewicz R et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31 (7): 1281–357.
17. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
18. Epstein BJ, Shah NK, Borja-Hart N. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013; 7: 246–59.
19. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 869–78.
20. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 2009; 3: 231–40.
21. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension 2009; 54: 19–22.
22. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
23. Ettehad D, Emdin CA, Kiran A. Anderson SG et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–67.
24. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
25. Tropeano A, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80–6.
26. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
27. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
28. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108 (9): 710–7.
29. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102 (13): 1503–10.
30. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366 (948): 895–906.
31. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic : a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15: 193–200.
32. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs 2014; 14: 137–45.
33. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
34. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther 2017; 6 (1): 91–104.
________________________________________________
2. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2224–60.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–8.
4. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
5. Ikeda N, Sapienz D, Guerrero R et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014; 92 (1): 10–9.
6. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh AG. Kardiologiia. 2014; 10: 4–12. [in Russian]
7. Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
8. Oganov R.G., Konstantinov V.V., Timofeeva T.N. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
9. Leonova M.V., Belousov Yu.B., Shteinberg L.L., Alimova E.E. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–8. [in Russian]
10. Chazova I.E., Ratova L.G. The combination therapy in patients with arterial hypertension. Systemic Hypertension. 2010; 7 (2): 6–10. [in Russian]
11. Oganov RG, Pogosova GN, Koltunov IE et al. Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. Eur J Cardiovasc Prev Rehabil 2011; 18 (2): 224–32.
12. Shal'nova S.A., Balabanova Iu.A., Konstantinov V.V. i dr. Arteril'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–60. [in Russian]
13. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15–8.
14. Konradi A.O. Znachenie priverzhennosti k terapii v lechenii kardiologicheskikh zabolevanii. Handbook for Practitioners Doctors. 2007; 6: 8–11. [in Russian]
15. Pogosova G.V., Koltunov I.E., Melik-Ogandzhanian G.Iu., Sokolova O.Iu. Priverzhennost' k lecheniiu serdechno-sosudistykh zabolevanii: problema vrachei i patsientov. Kardiovask. terapiia i profilaktika. 2009; 8 (4): 98–102. [in Russian]
16. Mancia G, Fagard R, Narkiewicz R et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31 (7): 1281–357.
17. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
18. Epstein BJ, Shah NK, Borja-Hart N. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013; 7: 246–59.
19. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 869–78.
20. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 2009; 3: 231–40.
21. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension 2009; 54: 19–22.
22. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
23. Ettehad D, Emdin CA, Kiran A. Anderson SG et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–67.
24. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
25. Tropeano A, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80–6.
26. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
27. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
28. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108 (9): 710–7.
29. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102 (13): 1503–10.
30. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366 (948): 895–906.
31. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic : a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15: 193–200.
32. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs 2014; 14: 137–45.
33. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
34. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther 2017; 6 (1): 91–104.
Авторы
Е.А.Темникова*
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*temnikovaomsk@mail.ru
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*temnikovaomsk@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*temnikovaomsk@mail.ru
________________________________________________
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*temnikovaomsk@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.